Company Filing History:
Years Active: 2020
Title: Heng-Hsiung Wu: Innovator in Cancer Therapy
Introduction
Heng-Hsiung Wu is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer therapy through his innovative research and patents. His work focuses on developing methods and compositions that target specific receptors involved in cancer progression.
Latest Patents
Heng-Hsiung Wu holds a patent for "Isolated antibodies against interleukin-17 receptor B (IL-17RB) for cancer therapy." This patent provides methods and compositions for the treatment and therapy of cancer. Specifically, it includes antagonists that are specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B. The patent discloses potent neutralizing antibodies specific for IL-17RB, along with methods for their manufacture and use. Additionally, the invention relates to antisense, RNAi, and shRNA compositions aimed at the prevention and treatment of cancer, particularly breast cancer and pancreatic cancer. He has 1 patent to his name.
Career Highlights
Heng-Hsiung Wu is affiliated with Academia Sinica, a leading research institution in Taiwan. His work at Academia Sinica has allowed him to focus on groundbreaking research in cancer therapy, contributing to advancements in medical science.
Collaborations
Heng-Hsiung Wu has collaborated with notable colleagues, including Wen-Hwa Lee and Jin-Yuh Shew. These collaborations have further enhanced his research and the impact of his inventions in the field of cancer treatment.
Conclusion
Heng-Hsiung Wu is a dedicated inventor whose work in cancer therapy has the potential to make a significant impact on treatment options for patients. His innovative approaches and collaborations continue to drive advancements in the medical field.